Related Experiment Video
Updated: Oct 9, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial
1Department of Obstetrics and Gynecology, Ralph L. Smith Research Center, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Abstract:
Epidemiological studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) significantly reduce the risk and mortality from colorectal cancer, in part by inhibiting prostaglandin (PG) synthesis. Cyclooxygenase (COX), the rate-limiting enzyme in PG biosynthesis, exists in two isoforms, COX-1 and COX-2. Genetic and pharmacological evidence suggest that COX-2 is involved in the development of colorectal cancer. We have previously shown that COX-2-derived prostacyclin participates in blastocyst implantation through activation of peroxisome proliferator activated receptor delta (PPARdelta), a member of the nuclear hormone receptor family. Furthermore, our recent studies suggest that a similar pathway is operative during colorectal carcinogenesis. These observations prompted us to examine whether the COX-2-PPARdelta signaling pathway is also involved during development of uterine adenocarcinoma. Here we describe for the first time the heightened expression of COX-2 and PPARdelta, but not COX-1, in uterine endometrial adenocarcinoma.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) and their inhibition of cyclooxygenase-2 (COX-2) show promise in cancer prevention. This study reveals heightened COX-2 and PPARdelta expression in uterine endometrial adenocarcinoma, suggesting a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to reduce colorectal cancer risk by inhibiting prostaglandin (PG) synthesis via cyclooxygenase (COX) enzymes.
- Genetic and pharmacological data implicate COX-2, but not COX-1, in colorectal cancer development.
- Previous research established a role for COX-2-derived prostacyclin and peroxisome proliferator activated receptor delta (PPARdelta) in blastocyst implantation.
Purpose of the Study:
- To investigate the potential involvement of the COX-2/PPARdelta signaling pathway in the development of uterine adenocarcinoma.
- To determine the expression levels of COX-1, COX-2, and PPARdelta in uterine endometrial adenocarcinoma.
Main Methods:
- Immunohistochemical analysis was employed to assess the expression of COX-1, COX-2, and PPARdelta.
- Uterine endometrial adenocarcinoma tissues were examined for heightened expression of these molecules.
Main Results:
- The study found significantly heightened expression of COX-2 and PPARdelta in uterine endometrial adenocarcinoma tissues.
- In contrast, COX-1 expression was not found to be heightened in these tissues.
- This is the first description of elevated COX-2 and PPARdelta in uterine endometrial adenocarcinoma.
Conclusions:
- The COX-2/PPARdelta signaling pathway is implicated in the pathogenesis of uterine endometrial adenocarcinoma.
- Targeting COX-2 or PPARdelta may represent a novel therapeutic strategy for uterine endometrial cancer.
- Further research is warranted to elucidate the precise mechanisms involved.